News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Napo Pharmaceuticals, Inc. Release: FDA Grants PDUFA Date of June 5, 2012 for Crofelemer


2/8/2012 6:47:19 AM

SAN FRANCISCO--(BUSINESS WIRE)--Napo Pharmaceuticals, Inc. (“Napo”) announced today that the New Drug Application (“NDA”) submitted on December 5, 2011 for crofelemer for the indication of chronic diarrhea in people living with HIV/AIDS on anti-retro viral therapy (“CRO-HIV”) was accepted for filing by the U.S. Food and Drug Administration (“FDA”) with a Priority Review designation. The FDA has set June 5, 2012, as the action date for the NDA under the Prescription Drug User Fee Act (“PDUFA”).

Read at BioSpace.com


comments powered by Disqus
   
Diarrhea
HIV/AIDS

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES